

CORRECTION

Open Access



# Correction : Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results

George A. Diaz<sup>1\*</sup>, Roberto Giugliani<sup>2</sup>, Nathalie Gufon<sup>3</sup>, Simon A. Jones<sup>4</sup>, Eugen Mengel<sup>5</sup>, Maurizio Scarpa<sup>6</sup>, Peter Witters<sup>7</sup>, Abhimanyu Yarramaneni<sup>8</sup>, Jing Li<sup>8</sup>, Nicole M. Armstrong<sup>9</sup>, Yong Kim<sup>10</sup>, Catherine Ortemann-Renon<sup>8</sup> and Monica Kumar<sup>8</sup>

**Correction :** *Orphanet Journal of Rare Diseases* (2022) 17:437  
<https://doi.org/10.1186/s13023-022-02587-0>

Following publication of the original article [1], we have been notified that Fig. 1 was published incorrectly. Correct Fig. 1 should be as per below:

Published online: 14 March 2023

The original article can be found online at <https://doi.org/10.1186/s13023-022-02587-0>.

\*Correspondence:

George A. Diaz  
[george.diaz@mssm.edu](mailto:george.diaz@mssm.edu)

<sup>1</sup> Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA

<sup>2</sup> Medical Genetics Service HCPA, Department of Genetics UFRGS, DASA and Casa Dos Raros, Porto Alegre, Brazil

<sup>3</sup> Reference Centre of Inherited Metabolic Disease in Femme Mère Enfant Hospital, Hospices Civils of Lyon, Lyon, France

<sup>4</sup> Manchester University National Health Service Trust, St Mary's Hospital, Manchester, UK

<sup>5</sup> Institute of Clinical Science for Lysosomal Storage Disorders, SphincS GmbH, Mainz, Germany

<sup>6</sup> University Hospital of Udine, Udine, Italy

<sup>7</sup> University Hospitals Leuven, Louvain, Belgium

<sup>8</sup> Sanofi, Bridgewater, NJ, USA

<sup>9</sup> Sanofi, Cambridge, MA, USA

<sup>10</sup> Sanofi, Paris, France

## Reference


1. Diaz et al. Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results 2022;17:437. <https://doi.org/10.1186/s13023-022-02587-0>

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



**Fig. 1** Patient disposition